EA201201274A1 - Ингибиторы протеинкиназ - Google Patents
Ингибиторы протеинкиназInfo
- Publication number
- EA201201274A1 EA201201274A1 EA201201274A EA201201274A EA201201274A1 EA 201201274 A1 EA201201274 A1 EA 201201274A1 EA 201201274 A EA201201274 A EA 201201274A EA 201201274 A EA201201274 A EA 201201274A EA 201201274 A1 EA201201274 A1 EA 201201274A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- diseases
- inhibitors
- kinases
- family
- proteinkinaz
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 108091007914 CDKs Proteins 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 abstract 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 abstract 1
- 108091007911 GSKs Proteins 0.000 abstract 1
- 102000004103 Glycogen Synthase Kinases Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Соединения общей формулы (I)где R, R, R, R, А, В и х принимают значения, указанные в данной заявке, являются ингибиторами протеинкиназ, в частности членами семейства циклин-зависимых киназ и/или семейства гликоген-синтаза-киназ-3, и пригодны для предотвращения и/или лечения любого типа боли, воспалительных нарушений, рака, иммунологических заболеваний, пролиферативных заболеваний, инфекционных заболеваний, сердечно-сосудистых заболеваний, нарушений обмена веществ, заболеваний почек, неврологических и невропсихиатрических заболеваний и нейродегенеративных заболеваний.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33986610P | 2010-03-10 | 2010-03-10 | |
PCT/EP2011/053574 WO2011110612A1 (en) | 2010-03-10 | 2011-03-10 | Inhibitors of protein kinases |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201201274A1 true EA201201274A1 (ru) | 2013-04-30 |
Family
ID=43809024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201201274A EA201201274A1 (ru) | 2010-03-10 | 2011-03-10 | Ингибиторы протеинкиназ |
Country Status (15)
Country | Link |
---|---|
US (3) | US8518948B2 (ru) |
EP (1) | EP2545037A1 (ru) |
JP (1) | JP2013521324A (ru) |
KR (1) | KR20130016244A (ru) |
CN (1) | CN102834380B (ru) |
AU (1) | AU2011226073B2 (ru) |
BR (1) | BR112012022511A2 (ru) |
CA (1) | CA2789189A1 (ru) |
EA (1) | EA201201274A1 (ru) |
HK (1) | HK1179623A1 (ru) |
IL (1) | IL221311A (ru) |
MX (1) | MX2012010471A (ru) |
NZ (2) | NZ601924A (ru) |
SG (1) | SG183192A1 (ru) |
WO (1) | WO2011110612A1 (ru) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012101064A1 (en) * | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyrimidine biaryl compounds as protein kinase inhibitors |
US9657009B2 (en) | 2012-11-08 | 2017-05-23 | Bristol-Myers Squibb Company | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
EP2922840B1 (en) | 2012-11-08 | 2016-12-21 | Bristol-Myers Squibb Company | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators |
CN104918940B (zh) | 2012-11-16 | 2017-03-08 | 默沙东公司 | 人磷脂酰肌醇3‑激酶δ的嘌呤抑制剂 |
US20160058751A1 (en) * | 2013-03-28 | 2016-03-03 | Cellworks Group, Inc. | Composition and method for treating cancer |
TW201534586A (zh) | 2013-06-11 | 2015-09-16 | Orion Corp | 新穎cyp17抑制劑/抗雄激素劑 |
TR201807411T4 (tr) * | 2013-10-17 | 2018-06-21 | Vertex Pharma | DNA-PK inhibitörleri. |
CN104437130B (zh) * | 2014-11-06 | 2016-08-31 | 沈鹏 | 一种可降解型中空纤维膜及其制备方法 |
HUE057343T2 (hu) | 2015-06-29 | 2022-05-28 | Astrazeneca Ab | Policiklusos amidszármazékok mint CDK9 inhibitorok |
JP7319977B2 (ja) * | 2017-12-06 | 2023-08-02 | リン バイオサイエンス,インコーポレイテッド | チューブリン阻害剤 |
BR112022003163A2 (pt) * | 2019-08-19 | 2022-05-17 | Pandion Operations Inc | Imunotolerância alvejada com um agonista de pd-1 |
EP4054570A1 (en) * | 2019-11-05 | 2022-09-14 | Dermira, Inc | Mrgprx2 antagonists and uses thereof |
JP2023505850A (ja) * | 2019-12-09 | 2023-02-13 | 石薬集団中奇制薬技術(石家庄)有限公司 | サイクリン依存性キナーゼ9阻害剤としての化合物及びその用途 |
CN113149996B (zh) * | 2020-05-12 | 2022-12-20 | 苏州阿尔脉生物科技有限公司 | 一种作为cdk9抑制剂的多环酰胺类衍生物、其制备方法及用途 |
US20230219961A1 (en) * | 2020-05-12 | 2023-07-13 | Suzhou Alphama Biotechnology Co., Ltd. | Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof |
WO2022143985A1 (zh) * | 2020-12-31 | 2022-07-07 | 清华大学 | 吡啶-2-胺衍生物及其药物组合物和用途 |
WO2022257965A1 (zh) * | 2021-06-09 | 2022-12-15 | 石药集团中奇制药技术(石家庄)有限公司 | 固体形式的周期蛋白依赖性激酶9抑制剂及其用途 |
WO2024009232A1 (en) * | 2022-07-05 | 2024-01-11 | Aurigene Oncology Limited | Substituted n-(pyridin-2-yl)acetamide derivatives as cdk12/13 inhibitors |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0784462B2 (ja) | 1986-07-25 | 1995-09-13 | 日清製粉株式会社 | ベンゾイミダゾ−ル誘導体 |
US5886191A (en) | 1997-08-18 | 1999-03-23 | Dupont Pharmaceuticals Company | Amidinoindoles, amidinoazoles, and analogs thereof |
ES2240449T3 (es) | 2000-02-25 | 2005-10-16 | F. Hoffmann-La Roche Ag | Moduladores receptores de adenosina. |
US20020052370A1 (en) * | 2000-07-06 | 2002-05-02 | Barber Christopher Gordon | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase |
DE10114138C2 (de) | 2001-03-16 | 2003-03-27 | Schering Ag | Cdk-inhibitorische Indirubinderivate mit erhöhter Löslichkeit |
ES2292753T4 (es) * | 2001-03-29 | 2009-02-16 | Vertex Pharmaceuticals Incorporated | Inhibidores de quinasas n-terminales c-jun (jnk) y otras proteina quinasas. |
DE10117204A1 (de) | 2001-04-06 | 2002-10-10 | Boehringer Ingelheim Pharma | In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
WO2002094825A1 (fr) | 2001-05-22 | 2002-11-28 | Banyu Pharmaceutical Co., Ltd. | Nouveau derive de spiropiperidine |
DE10129028A1 (de) | 2001-06-11 | 2003-01-02 | Schering Ag | Lösliche Cdk-inhibitorische Indirubinderivate |
AR036053A1 (es) | 2001-06-15 | 2004-08-04 | Versicor Inc | Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas |
US20040106647A1 (en) | 2002-06-28 | 2004-06-03 | Schneider Michael D. | Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy |
EP1608622A4 (en) | 2003-03-24 | 2009-04-01 | Merck & Co Inc | BIARYLSUBSTITUTED 6-LOW HETEROCYCLES AS SODIUM CHANNEL BLOCKERS |
SE0301963D0 (sv) | 2003-07-02 | 2003-07-02 | Astrazeneca Ab | New compounds |
GB0315966D0 (en) | 2003-07-08 | 2003-08-13 | Cyclacel Ltd | Compounds |
CA2533474A1 (en) | 2003-07-30 | 2005-02-10 | Shudong Wang | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors |
BRPI0412351A (pt) | 2003-07-30 | 2006-09-05 | Cyclacel Ltd | derivados e piridilamino-pirimidina como inibidores de proteìna quinase |
US8084457B2 (en) | 2003-09-15 | 2011-12-27 | Lead Discovery Center Gmbh | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
EP1679309A4 (en) | 2003-10-24 | 2007-03-28 | Ono Pharmaceutical Co | ANTISTRESS MEDICAMENT AND ITS MEDICAL USE |
AU2005236055B2 (en) | 2004-04-20 | 2011-10-06 | Transtech Pharma, Llc | Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators |
FR2878247B1 (fr) | 2004-11-19 | 2008-10-03 | Galderma Res & Dev | Nouveaux composes modulateurs des recepteurs de type ppary et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
MX2008014450A (es) * | 2006-05-18 | 2009-03-09 | Mannkind Corp | Inhibidores de cinasa intracelular. |
US7544306B2 (en) * | 2007-02-16 | 2009-06-09 | Honeywell International Inc. | Azeotropic fumigant compositions of methyl iodide |
SI2212297T1 (sl) * | 2007-10-12 | 2011-09-30 | Ingenium Pharmaceuticals Gmbh | Inhibitorji protein kinaz |
WO2009140519A1 (en) | 2008-05-14 | 2009-11-19 | Hydra Biosciences, Inc. | Compounds and compositions for treating chemical warfare agent-induced injuries |
EP2352730A4 (en) | 2008-11-07 | 2012-04-25 | Lundbeck & Co As H | BIOLOGICALLY ACTIVE AMIDES |
UA103918C2 (en) * | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
EP2473502A1 (en) * | 2009-09-04 | 2012-07-11 | Novartis AG | Heteroaryl compounds as kinase inhibitors |
-
2011
- 2011-03-10 CA CA2789189A patent/CA2789189A1/en not_active Abandoned
- 2011-03-10 JP JP2012556514A patent/JP2013521324A/ja not_active Ceased
- 2011-03-10 KR KR1020127025774A patent/KR20130016244A/ko not_active Application Discontinuation
- 2011-03-10 US US12/932,955 patent/US8518948B2/en not_active Expired - Fee Related
- 2011-03-10 EP EP11708026A patent/EP2545037A1/en not_active Withdrawn
- 2011-03-10 MX MX2012010471A patent/MX2012010471A/es active IP Right Grant
- 2011-03-10 EA EA201201274A patent/EA201201274A1/ru unknown
- 2011-03-10 NZ NZ601924A patent/NZ601924A/en not_active IP Right Cessation
- 2011-03-10 NZ NZ627520A patent/NZ627520A/en not_active IP Right Cessation
- 2011-03-10 WO PCT/EP2011/053574 patent/WO2011110612A1/en active Application Filing
- 2011-03-10 AU AU2011226073A patent/AU2011226073B2/en not_active Ceased
- 2011-03-10 CN CN201180012835.3A patent/CN102834380B/zh not_active Expired - Fee Related
- 2011-03-10 SG SG2012058145A patent/SG183192A1/en unknown
- 2011-03-10 BR BR112012022511A patent/BR112012022511A2/pt not_active IP Right Cessation
-
2012
- 2012-08-05 IL IL221311A patent/IL221311A/en not_active IP Right Cessation
-
2013
- 2013-06-09 HK HK13106821.7A patent/HK1179623A1/xx not_active IP Right Cessation
- 2013-08-27 US US14/011,057 patent/US9067888B2/en not_active Expired - Fee Related
-
2015
- 2015-06-11 US US14/736,589 patent/US20150272947A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20150272947A1 (en) | 2015-10-01 |
NZ601924A (en) | 2014-10-31 |
US20130345233A1 (en) | 2013-12-26 |
EP2545037A1 (en) | 2013-01-16 |
JP2013521324A (ja) | 2013-06-10 |
MX2012010471A (es) | 2012-10-09 |
IL221311A0 (en) | 2012-10-31 |
IL221311A (en) | 2015-08-31 |
BR112012022511A2 (pt) | 2016-08-30 |
NZ627520A (en) | 2015-10-30 |
AU2011226073A1 (en) | 2012-09-27 |
US8518948B2 (en) | 2013-08-27 |
CN102834380A (zh) | 2012-12-19 |
WO2011110612A1 (en) | 2011-09-15 |
US9067888B2 (en) | 2015-06-30 |
US20110224225A1 (en) | 2011-09-15 |
SG183192A1 (en) | 2012-09-27 |
CN102834380B (zh) | 2015-04-01 |
CA2789189A1 (en) | 2011-09-15 |
AU2011226073B2 (en) | 2015-05-28 |
KR20130016244A (ko) | 2013-02-14 |
HK1179623A1 (en) | 2013-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201201274A1 (ru) | Ингибиторы протеинкиназ | |
HK1203950A1 (en) | Inhibitors of protein kinases | |
EA201692166A1 (ru) | Гетероциклические ингибиторы глютаминазы | |
EA201390803A1 (ru) | Ингибиторы бромодомена и их применение | |
EA201591907A1 (ru) | Ингибитор киназ | |
EA201590391A1 (ru) | Пиразолилмочевины в качестве ингибиторов киназы | |
EA201400333A1 (ru) | Бензонитрильные производные в качестве ингибиторов киназ | |
EA201690746A1 (ru) | Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии | |
EA201400412A1 (ru) | ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
EA201390736A1 (ru) | Циклобутилзамещенные производные пирролопиридина и пирролопиримидина как ингибиторы jak | |
EA201290184A1 (ru) | Бензодиазепиновый ингибитор бромодомена | |
EA201290980A1 (ru) | Производные 1-амино-2-циклопропилэтилбороновой кислоты | |
EA201070328A1 (ru) | Соединения триазолопиридина и их применение в качестве ингибиторов ask | |
EA201290894A1 (ru) | Азетидиновые производные пиперидин-4-ила как ингибиторы jak1 | |
EA201291098A1 (ru) | Новые соединения 3,5-дизамещенного-3h-имидазо[4,5-b]пиридина и 3,5-дизамещенного -3h-[1,2,3]триазоло[4,5-b]пиридина как модуляторы протеинкиназ | |
EA201100794A1 (ru) | Замещенные пиримидины, предназначенные для лечения заболеваний, таких как рак | |
WO2012170827A3 (en) | Pyrazolopyrimidines and related heterocycles as ck2 inhibitors | |
EA201300471A1 (ru) | Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3 | |
EA201401212A1 (ru) | Производные пирролотриазинона | |
EA201401062A1 (ru) | Бициклические пиразиноновые производные | |
EP2614085A4 (en) | ANTI-IL-1 ANTIBODIES AND METHOD FOR THEIR USE | |
EA201290744A1 (ru) | Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов | |
EA201201676A1 (ru) | Гетероарильные соединения и композиции в качестве ингибиторов протеинкиназы | |
EA201170344A1 (ru) | Азаиндольные ингибиторы iap | |
EA201501187A1 (ru) | Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний |